v3.26.1
Consolidated Statements of Operations and Other Comprehensive Income (Loss) - USD ($)
12 Months Ended
Jun. 30, 2026
Jun. 30, 2025
Income Statement [Abstract]    
Revenue $ 4,215,175 $ 3,052,532
Cost of revenue (exclusive of amortization shown separately below) (2,165,181) (1,805,673)
Gross profit 2,049,994 1,246,859
Other income    
Government support income 677,776 816,901
Operating expenses    
Selling, general and administrative expenses (10,502,161) (8,918,468)
Development and regulatory approval expenses (3,371,292) (2,396,513)
Depreciation and amortization (1,163,847) (1,207,875)
Impairment of long-lived assets (298,555) (220,062)
Total operating expenses (15,335,855) (12,742,918)
Loss from operations (12,608,085) (10,679,158)
Other income (expense), net    
Interest expense (10,736) (26,339)
Realized foreign exchange gain (loss) 39,820 (911)
Interest income 110,329 101,522
Total other income, net 139,413 74,272
Net loss (12,468,672) (10,604,886)
Net loss attributable to non-controlling interest (37,697) (36,153)
Net loss attributable to Intelligent Bio Solutions Inc. (12,430,975) (10,568,733)
Other comprehensive (loss) income    
Foreign currency translation (loss) gain (218,242) 384,670
Total other comprehensive (loss) income (218,242) 384,670
Comprehensive loss (12,686,914) (10,220,216)
Comprehensive loss attributable to non-controlling interest (37,697) (36,153)
Comprehensive loss attributable to Intelligent Bio Solutions Inc. $ (12,649,217) $ (10,184,063)
Net loss per share, basic [1] $ (8.44) $ (20.04)
Net loss per share, diluted [1] $ (8.44) $ (20.04)
Weighted average shares outstanding, basic [1] 1,472,744 527,364
Weighted average shares outstanding, diluted [1] 1,472,744 527,364
[1] Common stock and per share amounts have been retroactively adjusted to reflect a 1-for-10 reverse stock split effected on December 15, 2025, throughout the consolidated financial statements unless otherwise stated.